Biotech entity
All 1 tracked stories fall under one category: pharma. Paul Rollinson is most often covered alongside Bill Meury, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Aug 1, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Paul Rollinson is most often covered alongside Bill Meury, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 2.5 across the same-window beat baseline. The 6 average consequence score is above the beat benchmark of 5.7 in the same window. We currently track 1 Biotech story that mention Paul Rollinson, all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Paul Rollinson. Shared-story counts are live from our verified record — not editorial picks.
Incyte's Q2 net product sales hit $1.49 billion on a 40% jump, powered by Jakafi's 7% growth and a one-time OPZELURA CMS benefit. The biotech raised full-year 2026 revenue guidance to $5.13-5.26 billion and is advancing Jakafi XR with formulary wins, targeting 3-5% demand share by year-end.
Source: Zolmax · Watch List News
Paul Rollinson is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
